Chengbin Wu

Company: EpiMab

Job title: Chief Executive Officer

Seminars:

A Novel Off-the-Shelf TCR Bispecific Platform for Cancer Immunotherapy 2:20 pm

• Plug and play approach for making TCR engagers integrated with our clinical validated TCE technology • Our approach was optimized from different design for best activity and IgG-like manufacturing properties • The platform was validated by testing several TCR targets in vitro and in vivo with potent preclinical activityRead more

day: Conference Day One

A Novel Off-the-Shelf TCR Bispecific Platform for Cancer Immunotherapy 2:00 pm

Plug and play approach for making TCR engagers integrated with our clinical validated TCE technology Our approach was optimized from different design for best activity and IgG-like manufacturing properties The platform was validated by testing several TCR targets in vitro and in vivo with potent preclinical activityRead more

day: DAY ONE TRACK 2 B